NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
The MATCH trial investigates the efficacy of treatment guided by genetic testing in patients with advanced refractory solid tumors, lymphomas, or multiple myeloma.
Asset / Drug
Drug and asset intelligence for NCI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Targeted Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.